Survey of proper use and occurrence of hyperkalemia after administration of MINNEBRO tablets in patients with hypertension - EBM Provider Cohort Study-

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031210422

Enrollment

15000

Registered

2021-11-12

Start date

2008-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Prescription of MINNEBRO tablets has commenced during the enrollment period (May 13, 2019 to May 31, 2023). The diagnosis of hypertension exists on the same month as the date of the first prescription of this drug during the enrollment period. The date of the earliest medical record after the start date of the data period is 180 days or more prior to the date of the first prescription of this drug.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Conduct serum potassium testing,, Development of hyperkalemia	—

Contacts

Public ContactContact GPSP

Daiichi Sankyo Co.,Ltd.

contact_gpsp@daiichisankyo.co.jp+81-3-6225-1059

Outcome results